What is Amalgam Rx?
Amalgam Rx operates at the intersection of digital health and life sciences, providing a robust platform for the development and deployment of regulated, clinically validated solutions. For over 15 years, the company has focused on reimagining care delivery, particularly within the chronic care ecosystem. Its end-to-end methodology supports life sciences partners in creating digital therapeutics and solutions that are utilized by patients and providers across three continents. With over 5 billion real-world evidence (RWE) data points generated, the company serves as a critical infrastructure provider for modern healthcare, enabling diverse business models that bring stakeholders closer together and unlock sustained value in a complex regulatory environment.
How much funding has Amalgam Rx raised?
Amalgam Rx has raised a total of $52.3M across 3 funding rounds:
Series A
$17.4M
Other Financing Round
$27M
Stock/Share Issuance
$7.9M
Series A (2023): $17.4M with participation from Novo Nordisk
Other Financing Round (2025): $27M led by Catalio Capital Management
Stock/Share Issuance (2025): $7.9M, investors not publicly disclosed
Key Investors in Amalgam Rx
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. The firm focuses on breakthrough biomedical technology companies and leverages a network of venture partners to provide expert insights and deal flow.
Novo Nordisk
Novo Nordisk is a global pharmaceutical company focused on developing innovative medicines and drug delivery systems for the treatment of serious chronic diseases. The company combines scientific research with advanced manufacturing capabilities to improve patient access to treatment worldwide.
What's next for Amalgam Rx?
Looking ahead, the infusion of capital will likely be directed toward expanding the company's digital footprint and enhancing its RWE data capabilities. As the healthcare industry shifts toward value-based care, Amalgam Rx is poised to capitalize on the increasing demand for integrated digital solutions that bridge the gap between pharmaceutical innovation and clinical practice. The strategic focus will likely involve scaling existing partnerships with global life sciences leaders and further refining its platform to support more complex, data-driven therapeutic interventions. By maintaining its commitment to clinical validation and regulatory compliance, the company is set to remain a cornerstone of the digital health transformation, driving efficiency and improved health outcomes on a global scale.
See full Amalgam Rx company page
